MedTrace Logo

tFUS to Enhance Alertness and Performance

NCT06461221 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL

Last updated 2025-09-08

No results posted yet for this study

Summary

The investigators goal is to target FUS energy to the centromedian nucleus of the thalamus (CMT), the core of arousal, which is inaccessible by traditional non-invasive neuromodulation devices. The CMT is an ideal stimulation target for augmenting alertness, as it is intimately linked with the cortex through the well described thalamocortical circuit to entrain network oscillations.

Conditions

  • Reaction Time
  • Alertness

Interventions

DEVICE

Transcranial Focused Ultrasound

Using MRI-guided targeting, we will administer focused ultrasound in one of the 4 stimulation conditions

DEVICE

Transcranial Focused Ultrasound

Using MRI-guided targeting, we will administer focused ultrasound in one of the 4 stimulation conditions

DEVICE

Transcranial Focused Ultrasound

Using MRI-guided targeting, we will administer focused ultrasound in one of the 4 stimulation conditions

DEVICE

Transcranial Focused Ultrasound

Using MRI-guided targeting, we will administer focused ultrasound in one of the 4 stimulation conditions

Sponsors & Collaborators

  • Attune Neurosciences Inc

    collaborator INDUSTRY

  • Nano-Bio Materials Consortium

    collaborator UNKNOWN

  • Medical University of South Carolina

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
22 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-08-01
Primary Completion
2025-08-01
Completion
2025-08-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06461221 on ClinicalTrials.gov